시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
무스카린성 아세틸콜린 수용체 시장 보고서(2025년)
Muscarinic Acetylcholine Receptor Global Market Report 2025
상품코드 : 1824297
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,646,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,606,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,566,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 무스카린성 아세틸콜린 수용체 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년 연평균 복합 성장률(CAGR)은 5.7%로 확대되어 23억 6,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 신경약리학 진보, 심혈관 질환 증례 증가, 안과 치료의 혁신, 호흡기계 치료의 출현, 소화기계 약제 파이프라인의 확대 등에 기인하고 있습니다. 예측 기간의 주요 동향으로는 안과 질환에서의 이용, 창약을 위한 전략적 파트너십, 조직 선택적 약물의 개발, 소화기 질환에서의 가능성, 맞춤형 치료 접근법에 대한 주목 등을 들 수 있습니다.

향후 5년간의 성장률 5.7%라는 예측은 지난 예측으로부터 0.1% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 영국과 벨기에에서 조달하는 수용체 표적 화합물과 고성능 스크리닝 키트의 비용을 밀어 올리고, 알츠하이머병이나 파킨슨병 연구의 지연을 악화시켜, 바이오파마의 연구개발(R&D) 비용을 증가시킴으로써 미국의 신경계 의약품 개발에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.

신경질환의 유병률 증가는 향후 무스카린성 아세틸콜린 수용체(mAChR) 시장의 성장을 이끌 것으로 예측됩니다. 신경 질환은 뇌, 척수, 말초 신경을 포함한 신경계에 영향을 미치는 병리학을 포함합니다. 무스카린성 아세틸콜린 수용체는 인지, 운동, 보상 등의 복잡한 행동을 제어하는데 중요한 역할을 하며, 다양한 신경질환의 유망한 치료 표적이 되고 있습니다. 예를 들어, 호주 정부 기관인 Australian Bureau of Statistics National Health Survey의 데이터에 따르면, 심장병과 뇌졸중의 추정 유병률은 2001년 4.1%에서 2022년 5.2%로 증가하여 130만 명이 병을 앓는 것으로 나타났습니다. 그 결과, 신경질환의 이환율 증가가 무스카린성 아세틸콜린 수용체 시장의 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Muscarinic acetylcholine receptors (mAChRs) belong to a class of G protein-coupled receptors (GPCRs) activated by the neurotransmitter acetylcholine. These receptors are widely distributed throughout the body, playing vital roles in numerous physiological processes, particularly within the central and peripheral nervous systems.

The primary types of muscarinic acetylcholine receptors include M1, M4, M5, among others. The M1 subtype is one of the five receptor subtypes involved in mediating the effects of acetylcholine. These receptors are G protein-coupled and participate in various physiological responses to acetylcholine. These receptors are accessible through different distribution channels such as hospitals, clinics, retail pharmacies, online pharmacies, and specialty centers. They find applications in several medical conditions such as chronic obstructive pulmonary disease, attention deficit hyperactivity disorder, Alzheimer's disease, memory impairment, psychiatric disorders, and more.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The muscarinic acetylcholine receptors market research report is one of a series of new reports from The Business Research Company that provides muscarinic acetylcholine receptors market statistics, including muscarinic acetylcholine receptors industry global market size, regional shares, competitors with a muscarinic acetylcholine receptors market share, detailed muscarinic acetylcholine receptors market segments, market trends and opportunities, and any further data you may need to thrive in the muscarinic acetylcholine receptors industry. This muscarinic acetylcholine receptors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The muscarinic acetylcholine receptor market size has grown steadily in recent years. It will grow from $1.82 billion in 2024 to $1.89 billion in 2025 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to neurological disorders treatment, cardiovascular disorders management, ophthalmic disorders therapies, respiratory conditions treatment, gastrointestinal disorders.

The muscarinic acetylcholine receptor market size is expected to see strong growth in the next few years. It will grow to $2.36 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to advancements in neuropharmacology, increasing cardiovascular disease cases, innovations in ophthalmic therapeutics, emerging respiratory therapies, expanding gastrointestinal drug pipeline. Major trends in the forecast period include utilization in ophthalmic conditions, strategic partnerships for drug discovery, development of tissue-selective agents, potential in gastrointestinal disorders, focus on personalized treatment approaches.

The forecast of 5.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. neurological drug development by driving up the cost of receptor-targeting compounds and high-throughput screening kits sourced from the UK and Belgium, exacerbating delays in Alzheimer's and Parkinson's research and increasing biopharma research and development(R&D) costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of neurological disorders is anticipated to drive the growth of the muscarinic acetylcholine receptor (mAChR) market in the future. Neurological disorders encompass medical conditions that impact the nervous system, including the brain, spinal cord, and peripheral nerves. Muscarinic acetylcholine receptors play a vital role in regulating complex behaviors such as cognition, locomotion, and reward, making them promising therapeutic targets for various neurological conditions. For example, data from the Australian Bureau of Statistics National Health Survey, a government agency in Australia, revealed that the estimated prevalence of heart disease and stroke increased to 5.2% in 2022, affecting 1.3 million individuals, compared to 4.1% in 2001. Consequently, the growing incidence of neurological disorders is fueling the expansion of the muscarinic acetylcholine receptor market.

The growing awareness and diagnosis of glaucoma are expected to significantly boost the muscarinic acetylcholine receptor market. Glaucoma, a progressive eye disease damaging the optic nerve, often associates increased intraocular pressure with muscarinic acetylcholine receptors' role in regulating it. According to the BrightFocus Foundation in October 2022, about 2.7 million out of three million Americans aged 40 or older with glaucoma suffer from open-angle glaucoma, the most prevalent type. Globally, the glaucoma population is anticipated to reach over 111 million by 2040 from the current 80 million. This increased understanding of glaucoma's link to muscarinic receptors drives the market growth.

The upsurge in research and development initiatives is a pivotal trend shaping the muscarinic acetylcholine receptor market. Companies in this sector are intensifying development activities to fortify their market position. For example, in January 2022, researchers at Merck introduced MK-6884, a carbon-11-labeled molecule detecting the M4 subtype of muscarinic cholinergic receptors. This innovation aids in measuring drug efficacy and neuropathological receptor loss in conditions such as Alzheimer's disease.

Major companies in the muscarinic acetylcholine receptor market are committed to innovating new products, seeking regulatory approval for schizophrenia treatment. Schizophrenia, a severe mental illness impacting thoughts, feelings, and behavior, often causes individuals to seem detached from reality. For instance, in September 2023, Karuna Therapeutics, Inc. submitted a New Drug Application (NDA) for KarXT (xanomeline-trospium) to the FDA for schizophrenia treatment. The company's dedication lies in pioneering innovative treatments for neurological and psychiatric illnesses, striving to address unmet medical needs.

In August 2024, AbbVie, a pharmaceutical company based in the U.S., acquired Cerevel Therapeutics for an undisclosed sum. This acquisition is part of AbbVie's strategy to enhance its neuroscience portfolio, particularly focusing on treatments for conditions such as schizophrenia, Parkinson's disease, and other neurological disorders. Cerevel Therapeutics, also a U.S.-based company, specializes in developing innovative therapies for neurological diseases, including schizophrenia, epilepsy, and Parkinson's disease, and focuses on creating treatments that target muscarinic acetylcholine receptors.

Major companies operating in the muscarinic acetylcholine receptor market include Heptares Therapeutics Ltd., Sumitomo Dainippon Pharma Co. Ltd., Anavex Life Sciences Corp., NeuroHealing Pharmaceuticals Inc., AstraZeneca plc, Karuna Pharmaceuticals Inc., Anven AlzDx Inc., Merck & Co Inc., Elsevier BV, Eurofins Discover X Corporation, Novus Biologicals LLC, Eli Lilly and Co., Novatein Biosciences Inc., Alomone Labs Ltd., GlaxoSmithKline plc, SK Bioscience Co., Johnson & Johnson, Pfizer Inc., Novartis AG, AbbVie Inc., Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Eisai Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sanofi SA, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the muscarinic acetylcholine receptor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global muscarinic acetylcholine receptor market during the forecast period. The regions covered in the muscarinic acetylcholine receptor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the muscarinic acetylcholine receptor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The muscarinic acetylcholine receptors market consists of sales of extracellular N-terminal segment, transmembrane domains (TM1-TM7), intracellular loops (IL1-IL3), intracellular C-terminal segment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Muscarinic Acetylcholine Receptor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on muscarinic acetylcholine receptor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for muscarinic acetylcholine receptor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The muscarinic acetylcholine receptor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Muscarinic Acetylcholine Receptor Market Characteristics

3. Muscarinic Acetylcholine Receptor Market Trends And Strategies

4. Muscarinic Acetylcholine Receptor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Muscarinic Acetylcholine Receptor Growth Analysis And Strategic Analysis Framework

6. Muscarinic Acetylcholine Receptor Market Segmentation

7. Muscarinic Acetylcholine Receptor Market Regional And Country Analysis

8. Asia-Pacific Muscarinic Acetylcholine Receptor Market

9. China Muscarinic Acetylcholine Receptor Market

10. India Muscarinic Acetylcholine Receptor Market

11. Japan Muscarinic Acetylcholine Receptor Market

12. Australia Muscarinic Acetylcholine Receptor Market

13. Indonesia Muscarinic Acetylcholine Receptor Market

14. South Korea Muscarinic Acetylcholine Receptor Market

15. Western Europe Muscarinic Acetylcholine Receptor Market

16. UK Muscarinic Acetylcholine Receptor Market

17. Germany Muscarinic Acetylcholine Receptor Market

18. France Muscarinic Acetylcholine Receptor Market

19. Italy Muscarinic Acetylcholine Receptor Market

20. Spain Muscarinic Acetylcholine Receptor Market

21. Eastern Europe Muscarinic Acetylcholine Receptor Market

22. Russia Muscarinic Acetylcholine Receptor Market

23. North America Muscarinic Acetylcholine Receptor Market

24. USA Muscarinic Acetylcholine Receptor Market

25. Canada Muscarinic Acetylcholine Receptor Market

26. South America Muscarinic Acetylcholine Receptor Market

27. Brazil Muscarinic Acetylcholine Receptor Market

28. Middle East Muscarinic Acetylcholine Receptor Market

29. Africa Muscarinic Acetylcholine Receptor Market

30. Muscarinic Acetylcholine Receptor Market Competitive Landscape And Company Profiles

31. Muscarinic Acetylcholine Receptor Market Other Major And Innovative Companies

32. Global Muscarinic Acetylcholine Receptor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Muscarinic Acetylcholine Receptor Market

34. Recent Developments In The Muscarinic Acetylcholine Receptor Market

35. Muscarinic Acetylcholine Receptor Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기